Literature DB >> 8347298

Regulation of B-cell activation and antigen presentation by Fc receptors.

W H Fridman1.   

Abstract

Fc receptors are a family of membrane-associated and soluble glycoproteins that mediate a vast array of functions triggered by immune complexes. The structures of murine and human Fc gamma and Fc epsilon receptors have been elucidated and the motifs involved in the activities that they mediate characterized during the past year. B-cell activation and differentiation may be enhanced by different Fc receptor isoforms either through an increased presentation of antigen associated with IgG (Fc gamma RIIb2, Fc gamma RIII, Fc epsilon RII), or the induction of cytokine synthesis by mast cells (Fc epsilon RI, Fc gamma RIII) and natural killer cells (Fc gamma RIII). Conversely, the crosslinking of Fc gamma RIIb1 to membrane Ig inhibits B-cell activation. Soluble forms of Fc receptor also regulate antibody production by enhancing interleukin-4-induced IgE synthesis (Fc epsilon RII) or inhibiting IgG synthesis (Fc gamma R). Different structural motifs are responsible for the different biological activities of each Fc receptor isoform.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8347298     DOI: 10.1016/0952-7915(93)90053-u

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  12 in total

1.  B-cell antigens within normal and activated human T cells.

Authors:  G P Sandilands; M Perry; M Wootton; J Hair; I A More
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

2.  Differential expression of CD32 isoforms following alloactivation of human T cells.

Authors:  G P Sandilands; S A MacPherson; E R Burnett; A J Russell; I Downie; R N MacSween
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

Review 3.  Structure and function of natural-killer-cell receptors.

Authors:  Peter D Sun
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

4.  Immunoregulatory characteristics of the in vitro anti-ssDNA response.

Authors:  C C Anderson; A Panoskaltsis; N R Sinclair
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

5.  Effect of preexisting immunity to Salmonella on the immune response to recombinant Salmonella enterica serovar typhimurium expressing a Porphyromonas gingivalis hemagglutinin.

Authors:  J J Kohler; L B Pathangey; S R Gillespie; T A Brown
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

6.  Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes.

Authors:  Johannes S Gach; Kane J V Mara; Celia C LaBranche; Marit J van Gils; Laura E McCoy; P J Klasse; David C Montefiori; Rogier W Sanders; John P Moore; Donald N Forthal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

7.  Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder.

Authors:  Shih Wee Seow; Juwita N Rahmat; Boon Huat Bay; Yuan Kun Lee; Ratha Mahendran
Journal:  Immunology       Date:  2008-01-22       Impact factor: 7.397

8.  Regulation and targeting of T-cell immune responses by IgE and IgG antibodies.

Authors:  R Bheekha Escura; E Wasserbauer; F Hammerschmid; A Pearce; P Kidd; G C Mudde
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

9.  Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.

Authors:  Deepak B Rawool; Constantine Bitsaktsis; Ying Li; Diane R Gosselin; Yili Lin; Nitin V Kurkure; Dennis W Metzger; Edmund J Gosselin
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

10.  Multiple mechanisms mediate enhanced immunity generated by mAb-inactivated F. tularensis immunogen.

Authors:  Bibiana V Iglesias; Constantine Bitsaktsis; Giang Pham; James R Drake; Karsten R O Hazlett; Kristen Porter; Edmund J Gosselin
Journal:  Immunol Cell Biol       Date:  2012-12-18       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.